Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302 | 0.85 | XDH (0.39) | ALDH1A1XDHGAAKMT2A | |
| SCHEMBL5607948 | 0.77 | XDH (0.31) | ALDH1A1XDHGAA | |
| SCHEMBL1683802 | 0.77 | ADORA2A (0.35) | — | |
| SCHEMBL9001851 | 0.73 | XDH (0.37) | ALDH1A1XDHGAAKMT2A | |
| SCHEMBL3291325 | 0.70 | CDK1 (0.47) | ALDH1A1XDHGAAKMT2A | |
| SCHEMBL1831279 | 0.69 | XDH (0.50) | ALDH1A1XDHKMT2A | |
| SCHEMBL1901244 | 0.68 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL22901881 | 0.67 | PI4KA (0.47) | ALDH1A1XDHGAAKMT2A | |
| SCHEMBL16769795 | 0.67 | CDK2 (0.54) | ALDH1A1GAAKMT2A | |
| SCHEMBL29159183 | 0.67 | ALDH1A1 (0.37) | ALDH1A1XDHGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0105404-A1 | Derivatives of steroid compounds linked to cyotoxic agents and process for their preparation | MERCK & CO. INC. (US) | 1984-04-18 | — | — | EP | claimed |
| CN-112584824-B | Nanoparticles | 新泰福托特股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116209439-A | Substituted N- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) arylsulfonamide analogs as cereblon modulators | 圣裘德儿童研究医院有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-111012921-A | Human antibody drug conjugates against tissue factor | 根马布股份公司 | 2020-04-17 | — | — | CN | disclosed |
| US-8460663-B2 | Stabilized liquid anti-RSV antibody formulations | MEDIMMUNE, LLC (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120321616-A1 | STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS | MEDLMMUNE, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120183543-A1 | DIAGNOSTIC BIOMARKERS FOR FIBROTIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| WO-2011037973-A1 | \"CLICK\" NANOPARTICLE CONJUGATES | NORTHWESTERN UNIVERSITY (US) | 2011-03-31 | — | — | WO | disclosed |
| CN-1901939-A | Treatment of Proliferative Diseases Using Antisense IAP Oligomers and Chemotherapeutic Agents | AEGERA THERAPEUTICS INC (CA) | 2007-01-24 | — | — | CN | disclosed |
| EP-1451205-A2 | ANTISENSE THERAPY USING OLIGONUCLEOTIDES THAT TARGET HUMAN KINESIN GENES FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040009156-A1 | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer | REINHARD CHRISTOPH (US) | 2004-01-15 | — | — | US | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003030832-A2 | ANTISENSE THERAPY USING OLIGONUCLEOTIDES THAT TARGET HUMAN KINESIN GENES FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |